5.6 The committee supports, in principle, the
access to products derived from cannabis for use in relation to particular
medical conditions where the use of those products has been proven to be safe and
5.7 The committee recommends that the Bill is
amended, if necessary, to establish mechanisms by which scientific evidence
about medicinal cannabis products can be assessed to determine their
suitability for use in the treatment of particular medical conditions.
5.10 The committee recommends that the Bill is amended
to address issues raised about its interaction with the existing Commonwealth
regulatory framework for medicinal products, including the Therapeutic Goods
Act 1989, the Narcotics Drug Act 1967 and relevant customs
5.13 The committee recommends that the Bill is amended
to ensure that medicinal cannabis products can be made available in Australia
consistent with Australia's international obligations, including under Articles
23 and 28 of the Single Convention on Narcotic Drugs (1961).
5.16 The committee recommends that the Commonwealth
government consult with its state and territory counterparts about the interrelationship
of relevant laws to ensure a consistent approach to accessing medicinal
cannabis and to facilitate compliance with any such access scheme and
Australia's international obligations.
5.18 Subject to the preceding recommendations, the
committee recommends that the Bill be passed.
Navigation: Previous Page | Contents | Next Page